Ultragenyx Pharmaceutical Statistics
Total Valuation
RARE has a market cap or net worth of $3.41 billion. The enterprise value is $3.73 billion.
Important Dates
The last earnings date was Tuesday, May 6, 2025, after market close.
Earnings Date | May 6, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
RARE has 94.38 million shares outstanding. The number of shares has increased by 21.44% in one year.
Current Share Class | 94.38M |
Shares Outstanding | 94.38M |
Shares Change (YoY) | +21.44% |
Shares Change (QoQ) | +0.63% |
Owned by Insiders (%) | 3.52% |
Owned by Institutions (%) | 94.16% |
Float | 91.01M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 5.72 |
Forward PS | 4.93 |
PB Ratio | 23.45 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 6.32 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 5.88.
Current Ratio | 2.40 |
Quick Ratio | 2.05 |
Debt / Equity | 5.88 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -8.35 |
Financial Efficiency
Return on equity (ROE) is -377.06% and return on invested capital (ROIC) is -30.38%.
Return on Equity (ROE) | -377.06% |
Return on Assets (ROA) | -24.51% |
Return on Invested Capital (ROIC) | -30.38% |
Return on Capital Employed (ROCE) | -50.34% |
Revenue Per Employee | $456,483 |
Profits Per Employee | -$424,713 |
Employee Count | 1,294 |
Asset Turnover | 0.45 |
Inventory Turnover | 18.87 |
Taxes
In the past 12 months, RARE has paid $2.45 million in taxes.
Income Tax | 2.45M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.76% in the last 52 weeks. The beta is 0.34, so RARE's price volatility has been lower than the market average.
Beta (5Y) | 0.34 |
52-Week Price Change | -11.76% |
50-Day Moving Average | 37.12 |
200-Day Moving Average | 46.17 |
Relative Strength Index (RSI) | 47.93 |
Average Volume (20 Days) | 1,039,221 |
Short Selling Information
The latest short interest is 5.54 million, so 5.87% of the outstanding shares have been sold short.
Short Interest | 5.54M |
Short Previous Month | 5.46M |
Short % of Shares Out | 5.87% |
Short % of Float | 6.08% |
Short Ratio (days to cover) | 5.95 |
Income Statement
In the last 12 months, RARE had revenue of $590.69 million and -$549.58 million in losses. Loss per share was -$5.88.
Revenue | 590.69M |
Gross Profit | -182.32M |
Operating Income | -513.57M |
Pretax Income | -586.86M |
Net Income | -549.58M |
EBITDA | -477.88M |
EBIT | -513.57M |
Loss Per Share | -$5.88 |
Full Income Statement Balance Sheet
The company has $494.44 million in cash and $889.70 million in debt, giving a net cash position of -$326.69 million or -$3.46 per share.
Cash & Cash Equivalents | 494.44M |
Total Debt | 889.70M |
Net Cash | -326.69M |
Net Cash Per Share | -$3.46 |
Equity (Book Value) | 151.25M |
Book Value Per Share | 1.54 |
Working Capital | 407.49M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$389.94 million and capital expenditures -$5.60 million, giving a free cash flow of -$395.54 million.
Operating Cash Flow | -389.94M |
Capital Expenditures | -5.60M |
Free Cash Flow | -395.54M |
FCF Per Share | -$4.19 |
Full Cash Flow Statement Margins
Gross margin is -30.87%, with operating and profit margins of -86.94% and -93.04%.
Gross Margin | -30.87% |
Operating Margin | -86.94% |
Pretax Margin | -92.63% |
Profit Margin | -93.04% |
EBITDA Margin | -80.90% |
EBIT Margin | -86.94% |
FCF Margin | n/a |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -21.44% |
Shareholder Yield | -21.44% |
Earnings Yield | -16.13% |
FCF Yield | -11.61% |
Dividend Details Analyst Forecast
The average price target for RARE is $94.00, which is 160.46% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $94.00 |
Price Target Difference | 160.46% |
Analyst Consensus | Strong Buy |
Analyst Count | 16 |
Revenue Growth Forecast (5Y) | 35.47% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
RARE has an Altman Z-Score of -2.69 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -2.69 |
Piotroski F-Score | 4 |